Overall, these data indicate that high expression levels of MAPK markers may identify HCC patients with poor prognosis and that targeting CIB1 may be a critical pharmaceutical intervention for lenvatinib monotherapy or combination therapy. Here, CIB1 is linked to hepatocellular carcinoma.